Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Ps...on this board...CHERRY is a study...not a poster.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Lemmiwinks Member Profile
 
Followed By 8
Posts 820
Boards Moderated 0
Alias Born 03/02/19
160x600 placeholder
Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire Inc. - 1/13/2020 6:00:10 AM
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook GlobeNewswire Inc. - 1/7/2020 6:00:10 AM
Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/6/2020 6:00:10 AM
VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events GlobeNewswire Inc. - 1/2/2020 6:00:10 AM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk PR Newswire (US) - 12/13/2019 6:14:00 PM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk GlobeNewswire Inc. - 12/13/2019 4:49:07 PM
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) f... GlobeNewswire Inc. - 12/2/2019 6:00:10 AM
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions GlobeNewswire Inc. - 11/18/2019 5:30:00 PM
Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award GlobeNewswire Inc. - 11/18/2019 12:15:12 PM
Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsule... GlobeNewswire Inc. - 11/14/2019 5:34:37 PM
Amarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking N... GlobeNewswire Inc. - 11/14/2019 6:59:25 AM
New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthca... GlobeNewswire Inc. - 11/11/2019 1:19:57 PM
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular R... GlobeNewswire Inc. - 11/11/2019 6:30:48 AM
Amarin to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/11/2019 5:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 5:29:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 6:37:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 6:31:38 AM
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/5/2019 5:00:00 AM
Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 11/4/2019 6:00:00 AM
Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019 GlobeNewswire Inc. - 10/24/2019 4:30:05 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognize... GlobeNewswire Inc. - 9/16/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 6:14:02 AM
Lemmiwinks   Friday, 11/29/19 11:35:53 PM
Re: crowin post# 230899
Post # of 243203 
Ps...on this board...CHERRY is a study...not a poster. And the WSJ article that will be written is for real..(either mega drug poney going it alone or more likely AMRN aqcuired by Pfizer or GILD).......Did a little shrimping in my time. Remember you from that past life......AMRN is the real deal. Ya can bank on it. Good luck. And it’s not even close to too late....but we already have a Captain and a Mrs. Captain....his message is AMRN good...Beer good....repeats it every Friday.
Just read Re-ducit article and review the ADCOM panel transcript from 11/14/19....the Jeffries report on AMRN by Jeff Yee is what I believe is closest to the truth among all the analysts reports albeit....very conservative on its peak sales projection. Ya read these three things....you will be up to speed. Right now we all waiting on the PDUFA label....anytime between now and 12/28/19. Plus health Canada before the end of December.

AMRN appears to be posting for the 400 more sales reps in US wich could be a go it alone play or a negotiating tactic for the BO. Many believe a tender offer is being discussed....just contingent on the expanded label so peak sales can be estimated....it’s wide open still....but I’m banking on $45 share either way...just the GIA is gonna be slower. Lastly there is a likely generic patent trial for January....could get settlement news in mid December or trial in January. So far looks to be strongly in AMRNs favor either way but settlement would be nicer as long as a buy out....trial win better for GIA....My prediction is wide label and $55/share BO. Others have other feelings. Again....if ya pull the trigger, good luck to you and welcome aboard.
Lemmi-

Also, there some really sharp dudes and duddettes on this board....both bears and bulls. Excellent reading all around. Enjoy.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist